Il Dong Pharmaceutical

KSC:249420 · KR7249420001

PharmaceuticalsSmall

360

Medium confidence — indicative

Value46

Profit price24

Cash yield38

Owner Earnings Yield75

Dividend Yield1

Sales & asset price35

Price/Sales42

EV / Gross Profit54

Price/Book9

Quality58

Returns on capital81

Return on Capital63

Cash Return on Capital88

Return on Equity93

Profit margins62

EBIT Margin45

Gross Profitability79

Cash backing42

Cash Conversion20

Accruals35

Owner Earnings Margin70

Growth62

Sales growth41

Profit growth82

Profit Growth81

Long-Term EPS Growth78

Owner Earnings Growth87

Reinvestment20

Price momentum97

Safety47

Debt load29

Debt serviceability19

Refinancing16

Debt Payback21

Liquidity34

Sentiment39

Analyst ratings22

Expectations trend50

Market mood69

Value Creation12/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Il Dong Pharmaceutical clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeKOSE

Employees67

Websiteildong.com

ISINKR7249420001

Last UpdateApr 2, 2026

Indices

KOSPI (South Korea)

Themes

CardiovascularPain ManagementUrologyWomen's HealthCentral Nervous SystemOncologyDiabetesNutraceuticalEndocrinologyHealth CareManufacturingPharmaceutical

Description

Analysis

Middle-of-the-road

Ildong Pharmaceutical Co., Ltd. sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is attractive. The owner-earnings multiple stands at 12.9×; owner earnings: the cash an owner could take out each year.

Growth is solid; the safety picture is adequate. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Il Dong Pharmaceutical with its peers

Hana Pharm

KSC:293480

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Boryung

KSC:003850

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Daewon Pharmaceutical

KSC:003220

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Yungjin Pharm

KSC:003520

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Dongwha Pharm

KSC:000020

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Ilsung IS

KSC:003120

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →